Novo Nordisk's new obesity drug hits 8,000-prescription mark in few weeks: Comparing with Saxenda, it took around four years

Few weeks into its launch, Novo Nordisk's new obesity treatment Wegovy is in high demand in the US, especially compared with the older drug Saxenda. Overall, Novo Nordisk's obesity business has had a strong second quarter, according to report.

Novo Nordisk Executive Vice President, Head of North America Operations, Doug Langa | Photo: Novo Nordisk / PR

Novo Nordisk's new obesity drug Wegovy certainly seems to have gotten off to a great start in the US following its approval from the US Food and Drug Administration (FDA) in early June.

Over the course of the first five weeks, more than 8,000 prescriptions have been issued for the new obesity drug, which is based around the GLP-1 analog semaglutide. This is a significantly faster development than what Novo Nordisk's other drug Saxenda went through, which was launched in 2015. It is based on the substance liraglutide, which is a predecessor to semaglutide.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP recommends nine new drugs, rejects one

Roche and Biogen are among the companies that have received recommendation for approval from the European Medicines Agency's committee (CHMP) at its September meeting. One Pfizer drug was the sole candidate to be rejected.

CEO at WSA: No clarity on EQT exit plans yet

The time horizon for the venture fund EQT's investment in WS Audiology should be ending soon, but according to Group CEO Eric Bernard, there is no clarity on when the potential changes might occur.

Further reading

Related articles

Trial banner

Latest news

See all jobs